Prospective targeted therapies for multiple myeloma
CAR T-cells: an advancement in treating MM?
Minimal residue disease (MRD) in multiple myeloma
CASTOR and POLLUX trial results for multiple myeloma reported at ASCO and EHA
Clinical management of venetoclax in multiple myeloma